JP2023510872A5 - - Google Patents

Info

Publication number
JP2023510872A5
JP2023510872A5 JP2022542899A JP2022542899A JP2023510872A5 JP 2023510872 A5 JP2023510872 A5 JP 2023510872A5 JP 2022542899 A JP2022542899 A JP 2022542899A JP 2022542899 A JP2022542899 A JP 2022542899A JP 2023510872 A5 JP2023510872 A5 JP 2023510872A5
Authority
JP
Japan
Prior art keywords
molecules
manipulated
gene
mhc
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022542899A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023510872A (ja
JP7853210B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/013140 external-priority patent/WO2021146222A1/en
Publication of JP2023510872A publication Critical patent/JP2023510872A/ja
Publication of JP2023510872A5 publication Critical patent/JP2023510872A5/ja
Application granted granted Critical
Publication of JP7853210B2 publication Critical patent/JP7853210B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022542899A 2020-01-13 2021-01-12 血液型抗原の修飾 Active JP7853210B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062960607P 2020-01-13 2020-01-13
US202062960617P 2020-01-13 2020-01-13
US62/960,617 2020-01-13
US62/960,607 2020-01-13
PCT/US2021/013140 WO2021146222A1 (en) 2020-01-13 2021-01-12 Modification of blood type antigens

Publications (3)

Publication Number Publication Date
JP2023510872A JP2023510872A (ja) 2023-03-15
JP2023510872A5 true JP2023510872A5 (cg-RX-API-DMAC7.html) 2024-01-22
JP7853210B2 JP7853210B2 (ja) 2026-04-28

Family

ID=74562041

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022542899A Active JP7853210B2 (ja) 2020-01-13 2021-01-12 血液型抗原の修飾

Country Status (7)

Country Link
US (1) US20230272429A1 (cg-RX-API-DMAC7.html)
EP (1) EP4090743A1 (cg-RX-API-DMAC7.html)
JP (1) JP7853210B2 (cg-RX-API-DMAC7.html)
CN (1) CN116234906A (cg-RX-API-DMAC7.html)
AU (1) AU2021207810A1 (cg-RX-API-DMAC7.html)
CA (1) CA3164591A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021146222A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
US20220213434A1 (en) * 2019-05-10 2022-07-07 The Regents Of The University Of California Modified pluripotent cells
AU2022277931A1 (en) * 2021-05-19 2023-11-30 Sana Biotechnology, Inc. Hypoimmunogenic rhd negative primary t cells
AU2022325231A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
CA3227108A1 (en) 2021-08-11 2023-02-16 Xiaomeng HU Genetically modified primary cells for allogeneic cell therapy
WO2023019208A2 (en) * 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Engineering cells for cell-based therapies, and associated compositions and methods
AU2022326565A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
AU2022325955A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
IL328729A (en) 2023-12-01 2026-07-01 Sigilon Therapeutics Inc Methods for producing stem cell-derived islet-like cells, as well as populations and compositions comprising them
CN118291605A (zh) * 2024-04-10 2024-07-05 深圳市血液中心(深圳市输血医学研究所) 一种基于ngs的多系统红细胞血型基因分型方法和试剂盒
CN118638907A (zh) * 2024-06-26 2024-09-13 中国人民解放军联勤保障部队第九六〇医院 一种用于检测易漏检类孟买表型的snp标记
CN119913243A (zh) * 2025-04-01 2025-05-02 浙江省血液中心 Abo血型变异体的snp位点、b亚型变异型血型鉴定试剂盒和方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US20140115726A1 (en) 2011-04-05 2014-04-24 Cellectis New tale-protein scaffolds and uses thereof
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
PT2931898E (pt) 2012-12-12 2016-06-16 Harvard College Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais
MX380562B (es) 2012-12-12 2025-03-12 Broad Inst Inc Modificaciones de sistemas, métodos y composiciones guía optimizadas para la manipulación de secuencias.
KR102955556B1 (ko) 2012-12-12 2026-04-22 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물
CN105209621B (zh) 2012-12-12 2021-05-25 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
EP3294342A4 (en) 2015-05-08 2018-11-07 President and Fellows of Harvard College Universal donor stem cells and related methods
EP3455635A1 (en) * 2016-05-13 2019-03-20 The University of Copenhagen A cell-based array platform
KR20240095477A (ko) * 2017-01-13 2024-06-25 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 면역조작된 만능 세포
CN110869494B (zh) 2017-06-12 2025-02-18 西奈卫生系统公司 无需全身性免疫遏制的同种异体移植物耐受
WO2019084531A1 (en) * 2017-10-27 2019-05-02 The Children's Hospital Of Philadelphia MODIFIED RED GLOBES HAVING PHENOTYPES OF RARE ANTIGENS
AU2019305585A1 (en) * 2018-07-17 2021-01-28 The Regents Of The University Of California Cells differentiated from immunoengineered pluripotent cells
EP3824075A4 (en) * 2018-07-17 2022-04-20 The Regents of The University of California CHIMERA ANTIGEN RECEPTOR T-CELLS DERIVED FROM IMMUNOMANIPULATED PLURIPOTENTS STEM CELLS
US20220213434A1 (en) * 2019-05-10 2022-07-07 The Regents Of The University Of California Modified pluripotent cells
US11162079B2 (en) * 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells

Similar Documents

Publication Publication Date Title
Lanza et al. Engineering universal cells that evade immune detection
Gornalusse et al. HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells
JP2022543112A5 (cg-RX-API-DMAC7.html)
Sedlik et al. Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells
JP2024144548A (ja) Hlaクラスiiタンパク質の発現能を有するhlaクラスii欠損細胞、hlaクラスi欠損細胞、及びその使用
JP2023002716A (ja) 主要組織適合遺伝子複合体e分子によって拘束されるt細胞を誘発するサイトメガロウイルスベクター及びhcmvベクターを含む組成物
Kohn et al. New frontiers in the therapy of primary immunodeficiency: from gene addition to gene editing
Patel et al. T-cell therapies for HIV: preclinical successes and current clinical strategies
CN114072516A (zh) 经修饰的腺病毒
US9228007B1 (en) Recombinant human progenitor cells, engineered human thymocytes, and engineered human T cells
Esrick et al. Genetic therapies for sickle cell disease
JP2018076329A (ja) Cd4+t細胞応答を向上するための修飾されたエピトープ
JP7523357B2 (ja) ウイルスベクター産生
CA3164591A1 (en) Modification of blood type antigens
CN108474003A (zh) 包含微小rna识别元件的cmv载体
Levesque et al. CRISPR-based therapeutic genome editing for inherited blood disorders
Sii-Felice et al. Innovative Therapies for Hemoglobin Disorders: K. Sii-Felice et al.
JP7714667B2 (ja) 改変ヒト人工多能性幹細胞の製造方法
Sheppard et al. Vaccination against endogenous retrotransposable element consensus sequences does not protect rhesus macaques from SIVsmE660 infection and replication
Hotblack et al. Dendritic cells cross-present immunogenic lentivector-encoded antigen from transduced cells to prime functional T cell immunity
AU2020370254B2 (en) Transgenic swine, methods of making and uses thereof, and methods of making human immune system mice
Porteus Knock-in editing: it functionally corrects!
Rans et al. The evolution of gene therapy in X-linked severe combined immunodeficiency
Kaneko et al. Uphill Battle of CRISPR/Cas9: A Budding Technology in Need of Refinement
栗原健 Suppression of HBV replication by the expression of nickase-and nuclease dead-Cas9